Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology and Hepatology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Podcast | Sexual health in older age

Dr Holly Thomas helps us unpack the needlessly taboo subject of sex and sexual health in women of older age.

Listen now
ADVANCED SEARCH
Log in
Top
Neurology and Therapy
Published in:

Open Access 23-02-2025 | Epilepsy in Children | REVIEW

Expert-Agreed Practical Recommendations on the Use of Fenfluramine in Developmental and Epileptic Encephalopathies Based on Clinical Experience and Literature Review

Authors: Vicente Villanueva, Victor Soto-Insuga, Patricia Smeyers, Ángel Aledo-Serrano, Rocío Sánchez-Carpintero, Juan García-Peñas, Antonio Gil-Nagel

Published in: Neurology and Therapy | Issue 2/2025

Login to get access

Abstract

Introduction

Fenfluramine (FFA) represents the latest therapeutic option approved for seizure management in Dravet syndrome (DS) and Lennox–Gastaut syndrome (LGS) for patients aged ≥ 2 years. This article provides expert guidance for optimizing FFA therapy to support clinical decision-making in these populations.

Methods

A panel of Spanish experts specialized in developmental epileptic encephalopathies (DEEs) has developed practical recommendations for the clinical use of FFA, focusing on key aspects of FFA management: mechanism of action, pharmacokinetics including drug interactions, titration, efficacy, safety and tolerability, contraindications, and considerations for its broader application in DEEs. The methodology adopted in this project was an expert-opinion, evidence-based approach.

Results

The panel issued targeted recommendations, including a modified titration strategy slower than the product guidelines, adjusted for possible antiseizure concomitant medications, and management of other concomitant treatments. Key efficacy indicators, such as reductions in seizure frequency and severity of the most disabling seizures, were emphasized as core measures for treatment evaluation. Periodic assessments of non-seizure outcomes and daily life activities are recommended during follow-up to comprehensively capture treatment outcomes. The panel noted that their clinical observations align with positive findings from clinical trials, suggesting a potential role for FFA in other DEEs, tailored to individual electroclinical and etiological profiles.

Conclusion

This article presents expert practical recommendations for the management and treatment optimization of FFA in patients with DEEs, supporting clinicians in achieving improved patient outcomes.
Literature
1.
Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58(4):512–21.CrossRefPubMedPubMedCentral
2.
Scheffer IE, Liao J. Deciphering the concepts behind “Epileptic encephalopathy” and “Developmental and epileptic encephalopathy.” Eur J Paediatr Neurol. 2020;24:11–4.CrossRefPubMed
3.
Guerrini R, Conti V, Mantegazza M, Balestrini S, Galanopoulou AS, Benfenati F. Developmental and epileptic encephalopathies: from genetic heterogeneity to phenotypic continuum. Physiol Rev. 2023;103(1):433–513.CrossRefPubMed
4.
Zuberi SM, Wirrell E, Yozawitz E, Wilmshurst JM, Specchio N, Riney K, et al. ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: position statement by the ILAE task force on nosology and definitions. Epilepsia. 2022;63(6):1349–97.CrossRefPubMed
5.
Specchio N, Wirrell EC, Scheffer IE, Nabbout R, Riney K, Samia P, et al. International league against epilepsy classification and definition of epilepsy syndromes with onset in childhood: position paper by the ILAE task force on nosology and definitions. Epilepsia. 2022;63(6):1398–442.CrossRefPubMed
6.
7.
Wirrell EC, Lagae L, Scheffer IE, Cross JH, Specchio N, Strzelczyk A. Practical considerations for the use of fenfluramine to manage patients with Dravet syndrome or Lennox-Gastaut syndrome in clinical practice. Epilepsia Open. 2024;9:1643.CrossRefPubMedPubMedCentral
8.
9.
10.
Martin P, Reeder T, Sourbron J, de Witte PAM, Gammaitoni AR, Galer BS. An emerging role for sigma-1 receptors in the treatment of developmental and epileptic encephalopathies. Int J Mol Sci. 2021;22(16):8416.CrossRefPubMedPubMedCentral
11.
Tupal S, Faingold CL. Serotonin 5-HT4 receptors play a critical role in the action of fenfluramine to block seizure-induced sudden death in a mouse model of SUDEP. Epilepsy Res. 2021;177: 106777.CrossRefPubMed
12.
13.
Martin P, Czerwiński M, Limaye PB, Muranjan S, Ogilvie BW, Smith S, et al. In vitro evaluation of fenfluramine and norfenfluramine as victims of drug interactions. Pharmacol Res Perspect. 2022;10(3): e00958.CrossRefPubMedPubMedCentral
14.
Cohen H, Mahajna G, Ben-Shushan T, Matok I, Eyal S. The extent of cytochrome P450 3A induction by antiseizure medications: a systematic review and network meta-analysis. Epilepsia. 2024;65(2):445–55.CrossRefPubMed
15.
Boyd B, Smith S, Gammaitoni A, Galer BS, Farfel GM. A phase I, randomized, open-label, single-dose, 3-period crossover study to evaluate the drug-drug interaction between ZX008 (fenfluramine HCl oral solution) and a regimen of stiripentol, clobazam, and valproate in healthy subjects. Int J Clin Pharmacol Ther. 2019;57(1):11–9.CrossRefPubMed
16.
Wheless JW, Fulton SP, Mudigoudar BD. Dravet syndrome: a review of current management. Pediatr Neurol. 2020;107:28–40.CrossRefPubMed
17.
Lagae L, Sullivan J, Knupp K, Laux L, Polster T, Nikanorova M, et al. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2019;394(10216):2243–54.CrossRefPubMed
18.
Sullivan J, Lagae L, Cross JH, Devinsky O, Guerrini R, Knupp KG, et al. Fenfluramine in the treatment of Dravet syndrome: results of a third randomized, placebo-controlled clinical trial. Epilepsia. 2023;64(10):2653–66.CrossRefPubMed
19.
Nabbout R, Mistry A, Zuberi S, Villeneuve N, Gil-Nagel A, Sanchez-Carpintero R, et al. Fenfluramine for treatment-resistant seizures in patients with Dravet syndrome receiving stiripentol-inclusive regimens: a randomized clinical trial. JAMA Neurol. 2020;77(3):300–8.CrossRefPubMed
20.
Knupp KG, Scheffer IE, Ceulemans B, Sullivan J, Nickels KC, Lagae L, et al. Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox– Gastaut syndrome: interim analysis of an open-label extension study. Epilepsia. 2022;64(1):139–51.CrossRefPubMedPubMedCentral
21.
Knupp K, Scheffer I, Ceulemans B, Sullivan J, Nickels K, Lagae L, et al. Efficacy and safety of fenfluramine for the treatment of seizures associated with Lennox-Gastaut syndrome: a randomized clinical trial. JAMA Neurol. 2022;79(6):554–64.CrossRefPubMedPubMedCentral
22.
Guerrini R, Specchio N, Aledo-Serrano Á, et al. An examination of the efficacy and safety of fenfluramine in adults, children, and adolescents with Dravet syndrome in a real-world practice setting: a report from the Fenfluramine European Early Access Program. Epilepsia Open. 2022;7(4):578–87.CrossRefPubMedPubMedCentral
23.
Valls Carbó A, Beltrán Á, Sánchez-Miranda Román I, et al. What have we learned from the real-world efficacy of FFA in DS and LGS? A post-marketing study in clinical practice. Epilepsy Behav. 2024;151: 109620.CrossRefPubMed
24.
Gil-Nagel A, Cross JH, Devinsky O, Ceulemans B, Lagae L, Knupp K, et al. Comprehensive scoping review of fenfluramine’s role in managing generalized tonic-clonic seizures in developmental and epileptic encephalopathies. Epilepsia. 2024;65(8):2186–99.CrossRefPubMed
25.
Strzelczyk A, Becker H, Tako L, Hock S, Hattingen E, Rosenow F, et al. Fenfluramine for the treatment of status epilepticus: use in an adult with Lennox-Gastaut syndrome and literature review. Neurol Res Pract. 2024;6(1):10.CrossRefPubMedPubMedCentral
26.
Pietrafusa N, Trivisano M, Casellato S, Correale C, Cappelletti S, De Liso P, et al. Fenfluramine below the age of 2 years in Dravet syndrome: What about safety and efficacy? Epilepsia. 2024;65(2):e7–13.CrossRefPubMed
27.
28.
Acha J, Pérez A, Davidson DJ, Carreiras M. Cognitive characterization of children with Dravet syndrome: a neurodevelopmental perspective. Child Neuropsychol. 2015;21(5):693–715.CrossRefPubMed
29.
Cainelli E, Favaro J, De Carli P, Luisi C, Simonelli A, Vecchi M, et al. Executive functions and attention in childhood epilepsies: a neuropsychological hallmark of dysfunction? J Int Neuropsychol Soc. 2021;27(7):673–85.CrossRefPubMed
30.
Bishop KI, Isquith PK, Gioia GA, Gammaitoni AR, Farfel G, et al. Improved everyday executive functioning following profound reduction in seizure frequency with fenfluramine: analysis from a phase 3 long-term extension study in children/young adults with Dravet syndrome. Epilepsy Behav. 2021;121(Pt A): 108024.CrossRefPubMed
31.
Bishop KI, Isquith PK, Gioia GA, Knupp KG, Scheffer IE, Nabbout R, et al. Fenfluramine treatment is associated with improvement in everyday executive function in preschool-aged children (<5 years) with Dravet syndrome: a critical period for early neurodevelopment. Epilepsy Behav. 2023;138: 108994.CrossRefPubMed
32.
Jensen MP, Gammaitoni AR, Salem R, Wilkie D, Lothe A, Amtmann D. Fenfluramine treatment for Dravet syndrome: Caregiver- and clinician-reported benefits on the quality of life of patients, caregivers, and families living in Germany, Spain, Italy, and the United Kingdom. Epilepsy Res. 2023;190: 107091.CrossRefPubMed
33.
Jensen MP, Gammaitoni AR, Galer BS, Salem R, Wilkie D, Amtmann D. Fenfluramine treatment for dravet syndrome: Real-world benefits on quality of life from the caregiver perspective. Epilepsy Res. 2022;185: 106976.CrossRefPubMed
34.
Moore JL, Carvalho DZ, St Louis EK, Bazil C. Sleep and epilepsy: a focused review of pathophysiology, clinical syndromes, co-morbidities, and therapy. Neurotherapeutics. 2021;18(1):170–80.CrossRefPubMedPubMedCentral
35.
Donnan AM, Schneider AL, Russ-Hall S, Churilov L, Scheffer IE. Rates of status epilepticus and sudden unexplained death in epilepsy in people with genetic developmental and epileptic encephalopathies. Neurology. 2023;100(16):e1712–22.CrossRefPubMedPubMedCentral
36.
Cross JH, Galer BS, Gil-Nagel A, Devinsky O, Ceulemans B, Lagae L, et al. Impact of fenfluramine on the expected SUDEP mortality rates in patients with Dravet syndrome. Seizure. 2021;93:154–9.CrossRefPubMed
37.
Samantha D. Fenfluramine: a review of pharmacology, clinical efficacy, and safety in epilepsy. Children (Basel). 2022;9(8):1159.
38.
Agarwal A, Farfel GM, Gammaitoni AR, Wong PC, Pinto FJ, Galer BS. Long-term cardiovascular safety of fenfluramine in patients with Dravet syndrome treated for up to 3 years: findings from serial echocardiographic assessments. Eur J Paediatr Neurol. 2022;39:35–9.CrossRefPubMed
39.
Elli C, Novella A, Pasina L. Serotonin syndrome: a pharmacovigilance comparative study of drugs affecting serotonin levels. Eur J Clin Pharmacol. 2024;80(2):231–7.CrossRefPubMed
40.
Devinsky O, King L, Schwartz D, Conway E, Price D. Effect of fenfluramine on convulsive seizures in CDKL5 deficiency disorder. Epilepsia. 2021;62(7):e98–102.CrossRefPubMedPubMedCentral
41.
42.
Geenen KR, Doshi SP, Patel S, Sourbron J, Falk A, Morgan A, et al. Fenfluramine for seizures associated with Sunflower syndrome. Dev Med Child Neurol. 2021;63(12):1427–32.CrossRefPubMed
43.
Aledo-Serrano Á, Cabal-Paz B, Gardella E, Gómez-Porro P, Martínez-Múgica O, Beltrán-Corbellini A, et al. Effect of fenfluramine on seizures and comorbidities in SCN8A-developmental and epileptic encephalopathy: a case series. Epilepsia Open. 2022;7(3):525–31.CrossRefPubMedPubMedCentral
Metadata
Title
Expert-Agreed Practical Recommendations on the Use of Fenfluramine in Developmental and Epileptic Encephalopathies Based on Clinical Experience and Literature Review
Authors
Vicente Villanueva
Victor Soto-Insuga
Patricia Smeyers
Ángel Aledo-Serrano
Rocío Sánchez-Carpintero
Juan García-Peñas
Antonio Gil-Nagel
Publication date
23-02-2025

Other articles of this Issue 2/2025

Content Validity of the Friedreich Ataxia Rating Scale in Patients with Spinocerebellar Ataxia

A Multi-omics Framework Based on Machine Learning as a Predictor of Cognitive Impairment Progression in Early Parkinson’s Disease

Effectiveness During 12-Month Adjunctive Brivaracetam Treatment in Patients with Focal-Onset Seizures in a Real-Life Setting: A Prospective, Observational Study in Europe

Surgical therapies for drug-resistant epilepsy

A Response to: Letter to the Editor Regarding Effects of Manual Acupuncture Versus Sham Acupuncture in patients with Post-Stroke Depression: A Randomized Clinical Trial

Letter to the Editor Regarding: Effects of Manual Acupuncture Versus Sham Acupuncture in Patients with Post-Stroke Depression: A Randomized Clinical Trial

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now
Video

Advances in Alzheimer's

Alzheimer's research and care is changing rapidly. Keep up with the latest developments from key international conferences, together with expert insights on how to integrate these advances into practice.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Healthcare IME
Learn more
Image Credits